Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + chemotherapy with or without all-trans retinoic acid in first-line advanced esophageal squamous cell carcinoma
ChiCTR2400090639Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tretinoin, tislelizumab, paclitaxel, cisplatin and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Overall survival. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
tretinointislelizumabpaclitaxelcisplatincarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400090639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090639.